Shane Lydon, M.D.; Decision and Order
DEA revoked Dr. Shane Lydon's registration for egregious controlled substance prescribing, signaling heightened enforcement against non-compliant prescribers. Pharmacies must verify prescriber DEA validity and report suspicious orders.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmacies filling controlled substance prescriptions from any prescriber, especially independent and retail chains. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA revoked Dr. Shane Lydon's registration, reinforcing that pharmacies must not fill prescriptions from revoked prescribers and must report suspicious orders.
Who it affects
Pharmacies filling controlled substance prescriptions from any prescriber, especially independent and retail chains.
What you must do
Review all controlled substance prescriptions from Dr. Lydon; verify DEA registration status of all prescribers; enhance suspicious order monitoring.
Deadline
Immediately; ongoing compliance required.
Source: https://www.federalregister.gov/documents/2026/07/14/2026-14137/shane-lydon-md-decision-and-order
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order